This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|September 1, 2021
Avantor Makes Multi-Year Investment in Hydration Capabilities for Biologics Production
Author(s)BioPharm International Editors
Avantor plans to address rising global demand for biologics with their investment in hydration capabilities.
Advertisement
Avantor announced a multi-year investment into its global hydration capabilities on Aug. 31, 2021 that includes a recently completed expansion to its facility in Gliwice, Poland, as well as a multi-stage expansion of its facility in Aurora, Ohio, that is expected to be completed by mid-2022.
The facility investments in Gliwice and Aurora will add to Avantor’s existing water for injection-quality (WFI) buffer manufacturing capabilities. The new equipment will provide enhanced capabilities and capacity to formulate and fill WFI-based hydration solutions, according to a company press release.
"Buffer management is a key area where biopharma manufacturers can save time while reducing risk and costs,” said Ger Brophy, executive vice-president of Biopharma Production at Avantor, in the press release. “This recent investment in our global hydration offering allows us to strengthen our [C]GMP [current good manufacturing practices] chemical manufacturing in Europe and the United States."
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5